Complicated pain management in a CYP450 2D6 poor metabolizer (Q36994597)

17 August 2017

title

Complicated pain management in a CYP450 2D6 poor metabolizer (English)

1 reference

17 August 2017

0 references

Adriana Foster

1

1 reference

17 August 2017

Elizabeth Mobley

series ordinal

2

1 reference

17 August 2017

Zixuan Wang

series ordinal

3

1 reference

17 August 2017

publication date

6 November 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

7

1 reference

17 August 2017

issue

4

1 reference

17 August 2017

page(s)

352-356

1 reference

Drug metabolism and variability among patients in drug response

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111/J.1533-2500.2007.00153.X

The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1533-2500.2007.00153.X

Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1533-2500.2007.00153.X

CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1533-2500.2007.00153.X

Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1533-2500.2007.00153.X

Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1533-2500.2007.00153.X

The role of opioids in cancer pain management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1533-2500.2007.00153.X

Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, Part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1533-2500.2007.00153.X

Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1533-2500.2007.00153.X

Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1533-2500.2007.00153.X

CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1533-2500.2007.00153.X

Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1533-2500.2007.00153.X

Activation of G-Proteins by Morphine and Codeine Congeners: Insights to the Relevance of O- and N-Demethylated Metabolites at μ- and δ-Opioid Receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1533-2500.2007.00153.X

A retrospective study of risk factors of akathisia in terminally ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1533-2500.2007.00153.X

10.1111/J.1533-2500.2007.00153.X

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference